Wilms' tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer.

Abstract

Despite novel chemotherapy treatments, pancreatic ductal adenocarcinoma (PDA) remains a lethal disease. New targeted cancer vaccines may represent a viable option for patients with PDA. The Wilms' tumor 1 (WT1) antigen is one of the most widely expressed tumor-associated antigens in various types of tumors, including PDA. Recent reports have indicated that WT1-targeted cancer vaccines for patients with PDA mediated a potent antitumor effect when combined with chemotherapy in preclinical and clinical studies. This review summarizes the early-phase clinical trials of WT1-targeted cancer vaccines (peptide vaccines and dendritic cell-based vaccines) for PDA. Moreover, we will discuss future strategies for PDA treatments using WT1-specific cancer vaccines combined with immune checkpoint therapies to maximize the clinical effectiveness of PDA treatments.

• Authors: Shigeo Koido, Masato Okamoto, Shigetaka Shimodaira, Haruo Sugiyama
• Journal: Immunotherapy (Immunotherapy) Vol. 8 Issue 11 Pg. 1309-1320 (11 2016) ISSN: 1750-7448 [Electronic] England
• PMID: 27993090 (Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't)

Chemical References

• Antigens, Neoplasm
• Cancer Vaccines
• Vaccines, Subunit
• WT1 Proteins
• WT1 protein, human

Topics

• Animals
• Antigens, Neoplasm (immunology)
• Cancer Vaccines (immunology)
• Carcinoma, Pancreatic Ductal (immunology, therapy)
• Clinical Trials as Topic
• Dendritic Cells (immunology, transplantation)
• Humans
• Molecular Targeted Therapy
• Vaccines, Subunit
• WT1 Proteins (immunology)